We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The COVID-19 pandemic, however, might have given the industry the much-needed push to increase the adoption of robotics to ensure continuation of operations amid lockdown restrictions.
Gene and cell therapy firm Oxford Biomedica is to invest £4 million to build digital and robotics capabilities that will help manufacture the next generation of cutting edge therapies.